TGV-Biomed proposes to develop Mul-1867 as a novel first-in-class antimicrobial agent for treatment of viral, bacterial and fungal eye infections.
Mul-1867 is the only drug candidate that kills all major bacterial, fungal and viral pathogens that are the causative agents of eye infections. Initial testing indicates Mul-1867 to be a significant breakthrough in the war on eye infections.
Based on its unique MOA, Mul-1867 renders to be:
1. Active against non-enveloped viruses, including adenovirus
2. Active against multiresistant bacteria and fungi
3. Active against microbial biofilms
4. Fast acting antimicrobial and antiviral agent, killing bacteria and inactivating viruses within 30 seconds